NDA 215960 · Glaxosmithkline
Utebzi
Tebipenem Pivoxil Hydrobromide · Oral
NovelPriority reviewCDER novel approval, Jun 17, 2026: To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jun 17, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
11
2 Phase 3, 0 recruiting
FAERS reports
6
5 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 17, 2026.
UTEBZI is a penem antibacterial indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca , and Enterococcus faecalis in adult patients who have limited or no alternative oral treatment options. ( 1.1 ) Usage to Reduce Development of Drug ‑ Resistant Bacteria To reduce the development of drug‑resistant bacteria and maintain the effectiveness of UTEBZI and other antibacterial drugs, UTEBZI should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Complicated Urinary Tract Infection (cUTI), Including Pyelonephritis UTEBZI is indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae species complex, Klebsiella oxytoca , and Enterococcus faecalis in adult patients who have limited or no alternative oral treatment options. 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug‑resistant bacteria and maintain the effectiveness of UTEBZI and other antibacterial drugs, UTEBZI should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: Tebipenem pivoxil is a prodrug of tebipenem, an antibacterial drug [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 17, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- UTEBZI · TEBIPENEM PIVOXIL HYDROBROMIDE EQ 300MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tebipenem Pivoxil Hydrobromide" as an intervention, any sponsor and status, largest first.
- A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)Pivotal-lookingCompleted
Spero TherapeuticsIndustry
NCT06059846 · 1,690 participants · Start Dec 21, 2023 · Primary completion Jan 27, 2025
Drug: TBP-PI-HBr; Imipenem-cilastatin and 2 more · For: Urinary Tract Infection; Acute Pyelonephritis
Sites: Miami, Florida; Buenos Aires, Argentina; Córdoba, Argentina · 85 sites in all
Spero TherapeuticsIndustry
NCT03788967 · 1,372 participants · Start Jun 3, 2019 · Primary completion May 20, 2020
Drug: TBPM-PI-HBr; Ertapenem and 2 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis
Sites: La Mesa, California; Miami, Florida; Blagoevgrad, Bulgaria · 96 sites in all
Spero TherapeuticsIndustry
NCT06727136 · 39 participants · Start Nov 20, 2024 · Primary completion Apr 22, 2025
Drug: TBP-PI-HBr · For: Healthy Participants
Sites: Salt Lake City, Utah
Spero TherapeuticsIndustry
NCT04178577 · 39 participants · Start Dec 6, 2019 · Primary completion Sep 6, 2020
Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) · For: Renal Impairment
Sites: Miami, Florida; Orlando, Florida
Spero TherapeuticsIndustry
NCT04421885 · 36 participants · Start Jun 1, 2020 · Primary completion Jul 11, 2020
Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference; Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test · For: Healthy Volunteers
Sites: Tempe, Arizona
Spero TherapeuticsIndustry
NCT04376554 · 30 participants · Start Feb 10, 2020 · Primary completion Apr 6, 2021
Drug: TBPM-PI-HBr; amoxicillin-clavulanate · For: Healthy Volunteers
Sites: Huddinge, Sweden
Spero TherapeuticsIndustry
NCT04238195 · 24 participants · Start Jan 19, 2020 · Primary completion Feb 26, 2020
Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo; Moxifloxacin 400mg and 1 more · For: TQT Study
Sites: Tempe, Arizona
Spero TherapeuticsIndustry
NCT04368585 · 20 participants · Start Jul 1, 2020 · Primary completion Aug 8, 2020
Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr); 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) and 1 more · For: Healthy Volunteers
Sites: Phoenix, Arizona
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction2
- nausea2
- anticonvulsant drug level below therapeutic1
- bacterial pyelonephritis1
- blood lactic acid increased1
- cholangitis1
- clostridium difficile infection1
- coagulopathy1
- disseminated intravascular coagulation1
- drug level decreased1
- epilepsy1
- fatigue1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 3 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
Eckburg PB, Muir L, Critchley IA, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects.
Patel G, Gupta VK, Gasink L, et al. · Antimicrob Agents Chemother 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
- Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT/QTc Intervals in Healthy Subjects.
Gupta VK, Maier G, Eckburg P, et al. · Antimicrob Agents Chemother 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects.
Rodvold KA, Gotfried MH, Gupta V, et al. · Antimicrob Agents Chemother 2022 · Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural
- Bioequivalence of two oral formulations of tebipenem pivoxil hydrobromide in healthy subjects.
Gupta VK, Patel G, Gasink L, et al. · Clin Transl Sci 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of tebipenem pivoxil hydrobromide on the normal gut microbiota of a healthy adult population in Sweden: a randomised controlled trial.
Sewunet T, Razavi M, Rosenborg S, et al. · Lancet Microbe 2024 · Randomized Controlled Trial, Clinical Trial, Phase I
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.